In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Corporatization” of health care, a process predicted decades ago, now refers to the general trend throughout the industry toward higher levels of integrated control by consolidated profit-seeking ...

A 63-year-old woman was evaluated for dyspnea and edema. Soft-tissue thickening was noted in the retroperitoneum and mediastinum and around the heart and vessels. A diagnosis was made.

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...

The Covid-19 vaccine resource center includes a collection of articles, FAQs, and related content to help educate and empower clinicians and their practice.

Earn AMA PRA Category 1 Credits™ using NEJM Weekly CME Activities. Complete online activities to specific NEJM articles to earn one CME credit per each successfully completed activity.

A total of 415 patients were assigned to cemiplimab (209) or placebo (206). The median follow-up was 24 months. Cemiplimab was superior to placebo with respect to disease-free survival (24 vs. 65 ...

This article from the FDA compares broad U.S. recommendations on Covid vaccination with those from other countries and announces the adoption of an evidence-based approach to such recommendations.

A total of 1176 patients received at least one dose of nerandomilast or placebo, of whom 43.5% were taking background nintedanib therapy at baseline. The adjusted mean change in the FVC at week 52 ...

A total of 278 patients were randomly assigned to the tenecteplase–thrombectomy group and 272 to the thrombectomy-alone group. Functional independence at 90 days was observed in 147 patients (52 ...

A total of 624 patients underwent randomization; 313 were assigned to receive vepdegestrant, and 311 to receive fulvestrant. Among the 270 patients with ESR1 mutations, the median progression-free ...